Circulating Cancer Stem Cell Markers in Breast Carcinomas: a Systematic Review Protocol

Overview

Journal Syst Rev

Publisher Biomed Central

Date 2017 Dec 21

PMID 29258583

Citations 9

Authors

Maryam Mansoori

Zahra Madjd

Leila Janani

Arezoo Rasti

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is one of the most common types of cancer in women worldwide. Recent studies have provided strong support for the cancer stem cell (CSC) hypothesis, which suggests that many cancers, including breast cancer, are driven by a subpopulation of cells that display stem cell-like properties. The hypothesis that a subpopulation of circulating tumor cells (CTCs) possesses many CSC-like hallmarks is reinforced by the expression of related molecular markers between these two cell populations. The aim of this study is to systematically review primary studies and identify circulating CSC markers in breast cancer patients.

Methods And Design: Relevant observational studies evaluating the expression of circulating breast cancer stem cell markers through October 31, 2016, will be searched in PubMed, SCOPUS, Embase, ISI Web of Science, and Google Scholar with no restriction on language. Full copies of articles identified by the search and considered to meet the inclusion criteria will be obtained for data extraction and synthesis. Two quality assessment tools will be used for evaluating observational studies like case control, which are the Hoy et al. suggested tool and Newcastle-Ottawa Scale (NOS), respectively. Publication bias will be assessed by funnel plots or Egger's test (i.e., plots of study results against precision), and data synthesis will be performed using Stata software (Stata Corp V.12, TX, USA).This systematic review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Discussion: Detecting cancer stem cells in blood will help clinicians to monitor cancer patients by obtaining as many samples as needed with a non-invasive method and in any stages; it is not possible to repeat sampling on working on tissue samples. By identifying cancer stem cells early in blood, it will be possible to distinguish metastasis in early stages.

Systematic Review Registration: CRD42016043810.

Citing Articles

Biology of breast cancer brain metastases and novel therapies targeting the blood brain barrier: an updated review.

Zhao H, Wang L, Ji X, Zhang L, Li C Med Oncol. 2023; 40(6):181.

PMID: 37202575 DOI: 10.1007/s12032-023-02047-0.

Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.

Krause W Cancer Drug Resist. 2022; 2(1):82-106.

PMID: 35582143 PMC: 9019178. DOI: 10.20517/cdr.2019.06.

Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients.

Maurer M, Pachmann K, Wendt T, Schott D, Wittig A Curr Oncol. 2021; 28(5):3507-3524.

PMID: 34590615 PMC: 8482075. DOI: 10.3390/curroncol28050302.

Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review.

Filip S, Vymetalkova V, Petera J, Vodickova L, Kubecek O, John S Int J Mol Sci. 2020; 21(15).

PMID: 32722130 PMC: 7432613. DOI: 10.3390/ijms21155255.

HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer PI3K/AKT/mTOR signaling.

Bai J, Chen W, Zhang X, Kang X, Jin L, Zhang H World J Stem Cells. 2020; 12(1):87-99.

PMID: 32110277 PMC: 7031759. DOI: 10.4252/wjsc.v12.i1.87.

References

Ali H, Dawson S, Blows F, Provenzano E, Pharoah P, Caldas C . Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res. 2011; 13(6):R118. PMC: 3326560. DOI: 10.1186/bcr3061. View

Soady K, Kendrick H, Gao Q, Tutt A, Zvelebil M, Ordonez L . Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast Cancer Res. 2015; 17:31. PMC: 4381533. DOI: 10.1186/s13058-015-0539-6. View

Wei W, Tweardy D, Zhang M, Zhang X, Landua J, Petrovic I . STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014; 32(10):2571-82. DOI: 10.1002/stem.1752. View

Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C . Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012; 65(9):934-9. DOI: 10.1016/j.jclinepi.2011.11.014. View

Chiotaki R, Polioudaki H, Theodoropoulos P . Cancer stem cells in solid and liquid tissues of breast cancer patients: characterization and therapeutic perspectives. Curr Cancer Drug Targets. 2015; 15(3):256-69. DOI: 10.2174/1568009615666150211102503. View

Toloudi M, Apostolou P, Chatziioannou M, Papasotiriou I . Correlation between Cancer Stem Cells and Circulating Tumor Cells and Their Value. Case Rep Oncol. 2011; 4(1):44-54. PMC: 3082489. DOI: 10.1159/000324403. View

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

Keller P, Arendt L, Skibinski A, Logvinenko T, Klebba I, Dong S . Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A. 2011; 109(8):2772-7. PMC: 3286919. DOI: 10.1073/pnas.1017626108. View

Werfalli M, Musekiwa A, Engel M, Ross I, Kengne A, Levitt N . The prevalence of type 2 diabetes mellitus among older people in Africa: a systematic review study protocol. BMJ Open. 2014; 4(6):e004747. PMC: 4067824. DOI: 10.1136/bmjopen-2013-004747. View

10.

Liu J, Shen R, Chen L, Ye Y, He G, Hua K . Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol. 2010; 3(4):328-37. PMC: 2872741. View

11.

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

12.

Deeks J, Dinnes J, DAmico R, Sowden A, Sakarovitch C, Song F . Evaluating non-randomised intervention studies. Health Technol Assess. 2003; 7(27):iii-x, 1-173. DOI: 10.3310/hta7270. View

13.

Friedrichs K, Ruiz P, Franke F, GILLE I, Terpe H, Imhof B . High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res. 1995; 55(4):901-6. View

14.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4):W65-94. DOI: 10.7326/0003-4819-151-4-200908180-00136. View

15.

Lipscomb E, Simpson K, Lyle S, Ring J, Dugan A, Mercurio A . The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res. 2005; 65(23):10970-6. DOI: 10.1158/0008-5472.CAN-05-2327. View

16.

Nel I, David P, Gerken G, Schlaak J, Hoffmann A . Role of circulating tumor cells and cancer stem cells in hepatocellular carcinoma. Hepatol Int. 2015; 8(3):321-9. DOI: 10.1007/s12072-014-9539-3. View

17.

Neumeister V, Agarwal S, Bordeaux J, Camp R, Rimm D . In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 2010; 176(5):2131-8. PMC: 2861079. DOI: 10.2353/ajpath.2010.090712. View

18.

Fillmore C, Kuperwasser C . Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?. Breast Cancer Res. 2007; 9(3):303. PMC: 1929090. DOI: 10.1186/bcr1673. View

19.

Chiba T, Kanai F, Iwama A, Yokosuka O . Circulating cancer stem cells: a novel prognostic predictor of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2014; 2(1):4-6. PMC: 3924641. DOI: 10.3978/j.issn.2304-3881.2012.09.02. View

20.

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View